Opendata, web and dolomites


Membrane fusion mediated dermal allergy immunotherapy

Total Cost €


EC-Contrib. €






Project "DermalTherapy" data sheet

The following table provides information about the project.


Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00


 Project objective

In this project we aim to develop a new delivery platform for allergy vaccines with a high efficacy and a high safety profile combining membrane fusion-mediated delivery and microneedle-based dermal delivery.

Background: Within the ERC Starting Grant “Direct Drug Delivery”, I developed a method for the controlled fusion of liposomes with cells. A set of complementary peptide amphiphiles (coilK and coilE), able to form heterodimeric coiled coils, were shown to induce targeted and efficient fusion between two opposing membranes. More importantly, we have shown that this method of fusion can be applied to liposomes and to live cells. Since liposomes can be used as drug or vaccine carriers, this enables the direct delivery of these compounds into live cells.

The Problem: Allergen-specific immunotherapy for treating allergies such as asthma is currently performed via chronic subcutaneous administration of allergen extracts to patients. Unfortunately, it requires monthly injections for several years to achieve the desired long-lasting immunological tolerance. These vaccinations are typically performed by intramuscular or subcutaneous injections, causing pain and stress. Therefore there is a need for a new and more efficient administration platform to achieve shorter, safer and more patient-friendly protocols.

Our solution: Dermal delivery of vaccines offers a great potential, due to the large number of immune cells present in the skin. In order to increase the efficacy of current allergen-specific immunotherapy, it is our idea to use the membrane fusion heterodimeric coiled coil peptide pair to induce efficient cellular uptake and processing of a commercially used allergen (rBet v1) encapsulated in liposomes in order to increase its efficacy as an allergy vaccine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DERMALTHERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DERMALTHERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

MitoGuide (2019)

Integration and adaptation of impaired mitochondrial fitness in orchestrating T cell dysfunction in the tumor microenvironment

Read More  


The Mass Politics of Disintegration

Read More  
lastchecktime (2022-05-23 6:03:06) correctly updated